Nearly 300 non-invasive diagnostic tests, are either already available in the market or under development across the world.

 Given the invasive and cost-intensive nature of tissue biopsies, there is a significant unmet need for safer and more patient-friendly cancer diagnostics that are capable of offering highly accurate, and actionable insights related to the disease.

 

To order this 350+ page report, which features 150+ figures and 200+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/liquid-biopsy-and-nicd-market/279.html

 

The financial opportunity within the liquid biopsy and other non-invasive cancer diagnostics market has been analyzed across the following segments:

§  Type of Tumor Marker

  • ctDNA
  • cfDNA
  • CTCs
  • Exosomes
  • Others

 

§  Application

  • Diagnosis / Early Diagnosis
  • Patient Monitoring
  • Recurrence Monitoring

 

§  Target Cancer Indication

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Bladder Cancer
  • Melanoma
  • Gastric Cancer
  • Pancreatic Cancer
  • Ovarian Cancer
  • Others

 

§  End Users

  • Hospitals
  • Research Institutes
  • Others

 

§  Key Geographical Regions 

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

 

The “Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers.”report features the following companies, which we identified to be key players in this domain:

§  Amoy Diagnostics

§  DiaCarta

§  HaploX Biotechnology

§  NeoGenomics

§  QIAGEN

§  Swift Biosciences

§  Sysmex Inostics

§  Thermo Fisher Scientific

Press Release: Variation 3 (Format 4)

 

Table of Contents

 

1. Preface

2. Executive Summary


3. Introduction

 

4. Non-Invasive Cancer Screening and Diagnosis

5. Market Landscape

 

6. Company Profiles

7. Partnerships and Collaborations

 

8. Funding and Investment Analysis

9. Liquid Biopsy: Initiatives of Big Pharma Players

10. Key Acquisition Targets

 

11. Other Non-Invasive Cancer Diagnostics

12. Market Sizing and Opportunity Analysis

13. Survey Insights

 

14. Conclusion

15. Executive Insights

 

16. Appendix 1: Tabulated Data

 

17. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/liquid-biopsy-and-nicd-market/279.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com

Comments

Post a Comment

Popular posts from this blog

The subcutaneous biologic drugs and affiliated technologies market is projected to be worth over USD 180 billion by 2030

    Subcutaneous drug delivery, given the use of tailored formulation development solutions, has brought about a paradigm shift in at-home healthcare, enabling users to administer (life-saving) medications without having to rely on medical professionals   Roots Analysis is pleased to announce the publication of its recent study, titled “ Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030 ” report to its list of offerings.   The report provides a detailed study on the current market landscape and future potential of biologics designed for subcutaneous administration. In addition, the study provides an in-depth analysis of the formulation technologies and drug delivery systems (focusing on large volume wearable injectors, autoinjectors, pen injectors, needle-free injectors, drug reconstitution systems, prefilled syringes and implants) that enable subcutaneous delivery of the biologic drugs. Amongst other elements, the r...
Read more

PRE-INSTALLED SINGLE-USE SENSORS FOR BIOPROCESSING-CASE STUDY

    During our research, we identified 31 pre-installed single-use sensors developed by various companies for bioprocessing. The current market landscape is predominantly characterized by the presence of large (38%) and small (37%) players. Notable examples of large players in this domain include ( in alphabetical order ) Cytiva Life Sciences (US), Hamilton (US) and Pall (US).   To Request Sample Pages -: https://www.rootsanalysis.com/reports/single-use-sensors-for-bioprocessing.html       Majority of the pre-installed single-use sensor systems are designed for both, research and biomanufacturing purposes. This is followed by those designed for only research purposes. Notable examples of products which are developed for both research and biomanufacturing applications, include ( arranged alphabetically ) ÄKTA ready XL sensor technology (Cytiva Life Sciences), Allegro™ MVP Single-Use System (Pall Corporation) and FUTURA pico (Aber Instruments)...
Read more

Global Psychedelic therapeutics market is estimated to be worth over USD 6.5 billion in 2030, predicts Roots Analysis

  A growing body of evidence suggests that using psychedelics, such as psilocybin and LSD, in combination with psychotherapy, can treat the symptoms of several mental health conditions, including depression and substance use disorders   Roots Analysis has announced the addition of “ Global Psychedelic Therapeutics Market, 2020-2030 ” report to its list of offerings.   The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapies over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes: §   A detailed assessment of the current market landscape of drug developers engaged in the development of psychedelic therapeutics .  §   Tabulated profiles of prominent psychedelic therapeutics developers. shortlisted on the basis of the number of pipeline...
Read more